Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA3 | P32297 | 7/20 | 0.78 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.78 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.78 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.78 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.78 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.78 |
| ▸ | CHRNG | P07510 | 1/20 | 0.78 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.78 |
| ▸ | CHRND | Q07001 | 1/20 | 0.78 |
| ▸ | LTA4H | P09960 | 6/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3942452 | 0.96 | CHRNA3 (0.81) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL905236 | 0.96 | CHRNA3 (0.81) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL905201 | 0.96 | CHRNA3 (0.81) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNA7 | |
| Hydrochloric Acid SCHEMBL7840031 | 0.94 | CHRNA3 (0.78) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNA7 | |
| Hydrochloric Acid SCHEMBL8439827 | 0.94 | CHRNA3 (0.78) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL401138 | 0.88 | CHRNB2 (1.00) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL29615733 | 0.88 | CHRNB2 (1.00) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL676026 | 0.88 | CHRNB2 (1.00) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNA7 | |
| SCHEMBL905208 | 0.88 | CHRNB2 (1.00) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNA7 | |
| Hydrochloric Acid SCHEMBL7836790 | 0.87 | CHRNB2 (0.97) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230225323-A1 | COMPOSITIONS AND METHODS FOR PARASITE CONTROL | PHILIP MORRIS PRODUCTS S.A. (CH) | 2023-07-20 | — | — | US | disclosed |
| US-20230225323-A1 | COMPOSITIONS AND METHODS FOR PARASITE CONTROL | PHILIP MORRIS PRODUCTS S.A. (CH) | 2023-07-20 | — | — | US | disclosed |
| CN-115698002-A | Compositions and methods for parasite control | 菲利普莫里斯生产公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2021260029-A1 | COMPOSITIONS AND METHODS FOR PARASITE CONTROL | PHILIP MORRIS PRODUCTS S.A. (CH) | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230225323-A1 | COMPOSITIONS AND METHODS FOR PARASITE CONTROL | TRHDE, CUTA, PIGS | CHRNA3 3915/4885CHRNB4 4655/4885CHRNB2 4302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.